A rigorous Phase 2B clinical trial conducted by MindBio Therapeutics has revealed that LSD microdosing is no more effective than a caffeine pill for treating major depressive disorder, potentially debunking years of anecdotal hype. The study, which involved 89 adult participants over an eight-week period, utilized the Montgomery-Åsberg Depression Rating Scale (MADRS) to measure clinical outcomes, finding that the psychedelic intervention was actually outperformed by the active placebo.
Clinical Reality Check: LSD vs. The Placebo Effect
While long-standing anecdotal reports have characterized microdosing as a “psychedelic Swiss Army knife” capable of enhancing focus and alleviating depression, the Melbourne-based biopharmaceutical company’s latest data suggests these benefits may be statistically insignificant. Patients in the trial received doses ranging from 4 to 20 micrograms of LSD—amounts far below the threshold for hallucinogenic effects. Despite reporting slight improvements in general well-being, their clinical depression scores lagged behind those who received a caffeine pill.
Justin Hanka, CEO of MindBio Therapeutics, described the findings as a definitive turning point for the industry. “It’s probably a nail in the coffin of using microdosing to treat clinical depression,” Hanka stated, noting that while the practice might improve a patient’s subjective mood, the changes fail to meet the threshold for clinical significance or statistical meaning.
The “Double-Dummy” Design and Patient Expectations
The study’s methodology utilized a “triple-blind, double-dummy” design to neutralize the high expectations often associated with psychedelic research. Participants were told they might receive LSD, caffeine, or methylphenidate (Ritalin), though the latter was never actually administered. This lowered the “expectancy effect,” as patients could attribute any perceived stimulation to a standard pharmaceutical stimulant rather than a “miracle” psychedelic.
This approach aligns with research from Jay A. Olson, a postdoctoral fellow at the University of Toronto. Olson’s previous study, “Tripping on Nothing,” demonstrated that participants could experience profound drug effects after consuming a complete placebo in a curated, high-expectation environment. “The placebo effect can be stronger than expected in psychedelic studies,” Olson explained, suggesting that the benefits of microdosing may be almost entirely driven by the patient’s mind and environment rather than the substance itself.
Scientific Disconnect: Why Prior Success Failed to Replicate
The Phase 2B results stand in stark contrast to MindBio’s earlier Phase 2A “open-label” trial, where patients knew they were receiving LSD. In that unblinded study, MADRS scores plummeted by 59.5%, with lasting improvements in anxiety and stress. The discrepancy highlights the critical importance of blinded, placebo-controlled trials in validating medical claims.
However, the trial design has faced sharp criticism from veteran psychedelic researcher Jim Fadiman. Fadiman argues that using caffeine as an “active placebo” taints the results because caffeine itself possesses psychoactive properties that can mask or compete with the effects of LSD. “Double-dummy is a remarkably apt term,” Fadiman remarked, suggesting that a sufficient dose of caffeine is effectively an anti-depressant in its own right.
Expert Backlash and the Strategic Pivot to AI
Despite the clinical setback, some proponents of microdosing remain unfazed. Author Ayelet Waldman, who documented her success using microdosing for mood disorders in her book A Really Good Day, told WIRED that the source of the improvement matters less than the result. “What mattered was that I felt better,” Waldman said, even if the shift was the “mother of all placebo effects.”
For MindBio, the path forward involves a significant strategic shift. After investing millions into microdosing research, Hanka is now pivoting the company toward “Booze A.I.,” an artificial intelligence application designed to detect blood alcohol concentration through vocal biomarkers. Reflecting on the volatility of the psychedelic sector, Hanka admitted that had he known the clinical outcomes six years ago, he likely would have avoided the microdosing field entirely.
